|Bid||0.0000 x 900|
|Ask||0.0000 x 1000|
|Day's Range||1.8000 - 1.8400|
|52 Week Range||1.4500 - 3.2800|
|Beta (3Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
If you're interested in Fibrocell Science, Inc. (NASDAQ:FCSC), then you might want to consider its beta (a measure of...
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.
EXTON, Pa., May 30, 2019 -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective.
EXTON, Pa., May 29, 2019 -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective.
The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business
“We achieved important milestones during the first several months of 2019 for our gene therapy clinical programs focused on devastating, rare genetic conditions of the skin and connective tissue with high unmet medical needs,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “Most recently, we announced our collaboration with Castle Creek Pharmaceuticals to develop and commercialize FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). “Furthermore, we completed a Type B end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of a Phase 3 clinical trial for FCX-007. Based on the FDA’s feedback from this meeting, we are incorporating their comments into our Investigational New Drug (IND) application for FCX-007, and expect to initiate the Phase 3 trial in the second quarter of 2019.
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2019 and recent operational highlights on Wednesday, May 15, 2019 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks. Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue.